NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Forecast & News

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing analysts' consensus estimates of ($1.71) by $0.25. The biopharmaceutical company earned $25.80 million during the quarter, compared to the consensus estimate of $28.88 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. The firm's quarterly revenue was up 119.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.74) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical updated its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $102-104 million, compared to the consensus revenue estimate of $100.68 million.

11 Wall Street analysts have issued 1 year price targets for Ultragenyx Pharmaceutical's stock. Their forecasts range from $59.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $73.55 in the next year. This suggests a possible upside of 29.1% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.

Press coverage about RARE stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 6,500,000 shares, an increase of 6.2% from the December 15th total of 6,120,000 shares. Based on an average trading volume of 531,700 shares, the short-interest ratio is currently 12.2 days. Approximately 12.1% of the company's stock are short sold. View Ultragenyx Pharmaceutical's Current Options Chain.

Some companies that are related to Ultragenyx Pharmaceutical include GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Dr.Reddy's Laboratories (RDY) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Gilead Sciences (GILD), Portola Pharmaceuticals (PTLA), GALAPAGOS NV/S (GLPG), Netflix (NFLX), GW Pharmaceuticals PLC- (GWPH), Palo Alto Networks (PANW), Intercept Pharmaceuticals (ICPT), TG Therapeutics (TGTX) and Nektar Therapeutics (NKTR).

Ultragenyx Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.00%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RARE stock can currently be purchased for approximately $56.97.

Ultragenyx Pharmaceutical has a market capitalization of $3.29 billion and generates $51.49 million in revenue each year. The biopharmaceutical company earns $-197,610,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical.

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]